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ABBREVIATIONS
APIGN -  Acute post infectious glomerular nephritis
GFR -  Glomerular filtration rate
ASO -  Anti strepto lysin
GBM -  Glomerular basement membrane
AS -  Alport syndrome
ESRD -  End stage renal disease
CKD - Chronic kidney disease
HSP -  Henoch scholein purpura
RFT -  Renal function test
CRP -   C-Reactive protein
ESR -  Erythrocyte sedimentation rate
URI -  Upper respiratory tract infection
UTI -  Urinary tract infection
RBC -  Red blood cells
ANA -  Anti nuclear antibody
LDH -  Lactate dehydrogenase
SLE -  Systemic lupus erythematosis
LM -  Light microscopy
EM -  Electron microscopy
GN -   Glomerular Nephritis
NS -  Nephrotic syndrome
ISKDC -   Nternational study kidney disease in children
HIV -    Human immunodeficiency  virus
AIDS -   Aquired immuno deficiency syndrome
NSAID -   Non steroidal anti inflammatory drug
FSGS -  Focal segmental glomerulosclerosis
SSNS -   Steroid sensitive nephrotic syndrome
SRNS -  Steroid resistant nephrotic syndrome
MCD -  Minimal change disease
HLA -  Human leukocyte antigen
MPGN -  Membrano proliferative glomerular nephritis
MCNS -  Minimal change nephrotic syndrome
SDNS -  Steroid dependant nephrotic syndrome
MMF -  Mycophenolate mofetil
IVIG -  Intra venous immunoglobulin
PCR -  Protein creatinine ratio
LFT -  Liver function test
HTN - Hyper tension
RPGN - Rapidly progressive glomerular nephritis
ELISA - Enzyme linked immunosorbent assay
RIA - Radio immuno assay
HUS - Hemolytic uremic syndrome
1INTRODUCTION
Glomerular   diseases generally present as  a  constellation  of
features  that includes hematuria,  edema , proteinuria  and  hypertension.
Glomerulonephritis  is caused  by number  of  disorders  that  cause
glomerular  injury due  to  inflammation. Some time it may progress to
renal failure if left  untreated.
Kidneys  are  a   pair   of    bean  shaped   reddish   brown   urinary
excretory organ located  by  each side of vertebral  column  T12 – L3  of
about  11cm X 6cm X 2.5cm , weighing 120 – 175g  each. Each  kidney
has cortex  and medulla. Renal cortex consists of  glomerulus,  proximal
and  distal tubules. Renalmedulla  consists of  the descending  and
ascending  limb of loop of   Henle  and   the  collecting ducts.
Each kidney has a  million of  Nephrons – the  functional  unit  of
kidney, consists of  2 parts.   1) Renal Corpuscle  -which   has glomerulus
and  Bowman’s capsule   2) Renal Tubules Kidney  cannot  regenerate  a
new  nephron1.
Glomerulus  - a  greek word  means  filter. Glomerulus  is  made up
of   tuft   of   capillaries  and   mesangium.  The  capillary  arises  from  the
afferent arteriole, the last division of  renal artery  and   they join to form
efferent arteriole.
2There  are  four  glomerular cell types – Endothelial cells,
podocytes or visceral epithelial cells, parietal epithelial cells and
basement  membrane Basement  membrane  is made up of  type IV
collagen,  Laminin , heparin sulfate and  proteoglycan. Podocytes  in
bowman’s capsule  wrap  the  capillaries  of glomerulus2.
Bowman capsule  filter  blood, holding   the larger  molecular
proteins  and  passing through  small  molecules  such  as  water, waste
products and  sugar  through slit diaphragm , which is made up of
Nephrin,CD2AP , calyxin and P-cadherin   proteins.  Glomerular diseases
is generally caused by genetic , immune mediated, hemodynamic ,
metabolic and coagulation disorders.
          Genetic  causes are  due to  the  mutation in   the exons of  DNA
encoding proteins of  glomerulus, resulting  in  congenital   glomerular
diseases. Immune mediated diseases is due to deposition of circulatory
antigen and  antibody  immune  complex. This mechanism is the most
common cause for glomerular  injury in children.
3Figure 1. Nephron
4AIM OF THE STUDY
? To study the clinical profile and glomerular diseases in  children
admitted.
? To study the outcome of glomerular diseases in   children admitted.
? To study the treatment response of glomerular  diseases in children
admitted.
5REVIEW OF LITERATURE
An inflammation of the glomeruli, bundles of tiny vessels inside
the kidney results in glomerular pathology . Glomerular injury may be
caused by various insults including hemodynamic, infection, immunity,
hereditary, toxicity and metabolic diseases. The waste products and
excess water from the blood could not be filtered by damaged
glomerulus. Hence  the kidney  becomes enlarged, fatty and congested .
This results in hematuria, edema,oliguria, hypertension, anemia,
ascites, proteinuria  and hypoalbuminemia.  Early diagnosis and
management  results in good prognosis.
HISTORICAL ASPECTS
Aristotle (384-322 BC) described excess liquid  from blood is
separated by kidney and  modifies the liquid, which is excreted  via
ureter , bladder and Urethra3.
Galen (130-200 AD) described the urine  formation.
? 1666 – Marcello Malphigi 4,5 -   described   micro  anatomy   of
kidney, formation of urine through  filter in between blood and
renal tubules.
? 1816-1892 – William Bowman – Glomerular  capillary
network,
6? Giovani  Bathista  Morgagini6  father of Pathological anatomy.
? 1789-1858 – Richart Bright7 – Macrosopic  appearance of the
diseased kidney.
? 1837   Gabriel Valentine- Renal histology of massive
proteinuria
? 1809-1855 – Friedrich  Henle – Loop of  Henle.
? 1885-1966 - Sir Arthur Allis – Clinicopathology of  glomerular
diseases4.
? 1905-Fried rich Muller- Inflammatory  glomerular  nephritis
? 1913-Munk-  lipoid nephrosis
? 1944 - Nils Alwell  - Renal needle biopsy
? 1955 -  Mellors  - Immune fluorescence  / microscopy on renal
tissue
? 1955-   Schering & Cepjohn-  prednisone  and  prednisolone
was  introduced.
? 1970 - 2010 - New numerous renal pathologists  defined  the
etiology ,pathogenesis ,clinic  pathology  of  glomerular
disease.
7Epidemiology
Glomerular   diseases  are the  one of the  common causes of end
stage renal diseases world  wide probably due to prevalence of infectious
diseases in developing countries8.
Glomerulonephritis  accounts 10-15% of  glomerular  diseases  in USA.
In  GN,  Males   are   more   prone   than   females9 particularly
affecting   children  and young  adolescents  of  5-15  years of age10
IgA nephropathy  is most common GN  world wide.
The incidence  of  post infectious   GN  has  been  reduced  in most
of western countries, but  remains  more common  in countries like
Africa, The Caribbean, Pakisthan, Malaysia, India   and  South
America10.
The reduction  in  incidence is due to  better  health care system
and economic  conditions  improvement.
Minimal  change disease  is  most common cause  for nephrotic
syndrome in children of  1-8 year  accounts  for  90%  but also can occur
in older children and adults11, Boys are  more prone than  girls.
8Classification of Primary Glomerular Disease Based on Clinical
Syndrome
Nephrotic Syndrome
? Minimal change disease
? Membranous glomerular nephropathy
? Focal segmental glomeruli sclerosis
? Membranous proliferative  glomerulonephritis
? C1q nephropathy
? Fibrillary  glomerulonephritis
Acute Glomerulonephritis
? Membranous  proliferative  glomerulonephritis
? IgA  nephropathy,
? Post infective GN
Rapidly Progressive Glomerulonephritis
? Antiglomerular basement membrane disease
? Immune complex crescentic glomerulonephritis
? Pauci-immune crescentic glomerulonephritis
? IgA nephropathy
? Membrano proliferative  glomerulonephritis
Asymptomatic Hematuria and/or Proteinuria
? IgA nephropathy
9? Membrano proliferative  glomerulonephritis
Figure. 2 Glomerulus  & Its Pathology
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TABLE 1.
Common Clinical Syndromes of Primary Glomerular Diseases
Symptom NephroticSyndrome
Acute
Glomerulone
phritis
Rapidly
Progressive
Glomerulonephr
itis
Asymptoma
tic
Hematuria
and/or
Proteinuria
Proteinuria >3.5 g/1.73 m2 /per day
nephrotic
range nephrotic range
No or non-
nephrotic
range
Hematuria
Variable and
usually
monomorphic
RBC casts
and
dysmorphic
RBCs
RBC casts and
dysmorphic
RBCs
dysmorphic
with RBC
casts)
Blood
pressure
Normo- or
hypertension Hypertension Hypertension
Normotensi
on
GFR Variable Rapiddecline)
Progressive
decline
Decline
uncommon
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Figure 3.  Pathogenesis Of Glomerular  Disease
Figure 4. The spectrum of glomerular diseases
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NEPHROTIC  SYNDROME IN CHILDREN (NS)
Nephrotic   Syndrome is a common renal disorder in children
characterized by altered permeability of  glomerular capillary wall results
in massive loss of urinary protein. This  can be acute or transient, may be
chronic and  progressive like FSGS. Some of disease may be remitting
and relapsing  like minimal change NS12.
ACCORDING  TO ISKDC ( INTERNATIONAL  STUDY OF
KIDNEY DISEASE IN CHILDREN), a child is said to have Nephrotic
syndrome if,
Proteinuria  (more than 40mg  /m2 / Hr)
Hypoalbuminimia  (less than 2.5g/dl).
Hyperlipidemia  (more than 200mg/dl).
Edema
13
Figure 5. Nephrotic Syndrome Presentation I
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Figure 6. Nephrotic Syndrome Presentation II
15
EPIDEMIOLOGY
? Annual  incidence  ranges from 2 – 7 per / Lakh Children,
prevalence  12 – 16 / Lakh13.
? Higher incidence in South Asia14  than  Europe.  Increased
incidence of  primary NS  in India, Japan, south west Asia15 .
In Africa – primary NS is very rare.  Secondary NS is more
common .
? Male to female ratio is 3:2 in various studies in children less
than8 years16, in old children   M:F is 1:1.
CLASSIFICATION
Primary
Secondary
Infantile.
Congenital
Primary NS – Intrinsic to kidney
? Minimal change nephrotic syndrome – Most common  cause  of
NS in children.
? Focal  segmental  glomerulosclerosis.
? Membrano-proliferative GN.
16
? Membranous  nephropathy.
? C3 GN.
? IgA nephropathy.
? Diffuse mesangial proliferation.
Secondary NS
? Infection : Hepatitis B& C , Toxoplasmosis, Cytomegalo
virus , Congenital , Syphilis, Rubella, Malaria  , HIV/ AIDS.
? Drugs – Lithium, NSAID , interferon, mercury,
penicillamine, gold, heroin.
? Systemic Disease – Malignancies like lymphomas,
leukemia, systemic lupus erythematosis ,Vasculitis,
Wegeners Granmulomatosis, polyarthritis nodosa,
microscopic polyangitis , Henoch scholein purpura and
Churg – Strauss syndrome (eosinophilic  granulomatosis) .
? Immune complex associated – post strepto coccal  GN.
Infantile NS : It occurs before 3months of life.
Congenital NS : it occurs between 4-12 month of age.
Causes :
? Finish type congenital NS (NPHS1- Nephrin gene).
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? Denys – Drash syndrome (wilms tumour suppressor gene
WT1).
? Frasier syndrome (wilms tumour suppressor gene WT1).
? Diffuse mesangial sclerosis (WT, PLCE1, phospholipase C,
epsilon 1 gene).
? Autosomal recessive, familial FSGS (NPHS2, podocin gene).
? Autosomal  dominant , familial FSGS (ACTN4,  ? actinin 4,
TRPC6).
? Nail patella syndrome (LMX1B).
? Pierson syndrome – (LAMB2).
? Galloway –Mowat syndrome.
? Schimke immune osseous dysplasia (SMARCAL1).
Two types of NS, based of response to steroids.
? Steroid sensitive NS (SSNS).
? Steroid Resistant NS (SRNS).
Common definitions to define the course of nephrotic syndrome
Nephrotic syndrome: Edema, nephrotic range proteinuria (>40
mg/m²/hr on timed sample, spot albumin to creatinine ratio >2mg/mg);
hypoalbuminaemia (<2.5 g/dl)
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Relapse
Urinary  protein  excretion  >40  mg/m²/h;  >  3+  by  dipstick  for  3
consecutive days.
Remission
Urinary protein excretion <4 mg/m²/h; nil or trace by dipstick on
spot sample for 3 consecutive days.
Frequent relapse
Two or more relapses in 6 months of initial response; 4 or more
relapses in any 12 months period.
Steroid dependence
Occurrence of 2 consecutive relapses during steroid therapy or
within 2 week of its cessation.
Steroid resistance
Failure to achieve remission after 4 wk of daily therapy with oral
prednisolone  at  a  dose of  2 mg/kg/day.
Pathogenesis
The pathogenesis is unclear in MCD, but there is strong evidence
of immune dysregulation, involving cell mediated immunity. This view in
supported by the tendency of  NS to manifest and relapse after viral
19
infections or an atopy, the association with HLA antigens and Hodgkin’s
lymphoma and its response to steroids and cyclosporine.
T cell function abnormality have been variably reported in a
number of patients with MCD17,18,19.
Cytokines bias
T Cells – Type I – (2 interferon, IL2) cytokines predominate in cell
mediated immunity .
           Type II  - (IL4, IL10, or IL13) cytokines – atopy   association.
       B Cells  - Production of Ig G4 and IgE20.
Increased plasma levels of IgE1, normal IgG4, association with
type 2 cytokine bias in subjects with MCD. Increased production of
cytokines especially IL4 is reported21.
In vitro studies shows that podocytes express receptors for IL4 and
IL1321. Activation of these receptors, by respective cytokines disrurpts
glomerular permeability resulting  in proteinuria.
Vascular permeability factors
Factors like vascular endothelial growth factors, heparinase  and
hemopexin22 play  a role in increased glomerular  permeability in patients
with MCD and FSGS. Hoff et al23 has showed  dysregulated  heparinase
synthesis in children with steroid sensitive NS.
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Podocyte injury
Recent evidence suggests, primary  defect in idiopathic NS in at the
level of podocyte, the glomerular visceral epithilial cell.  Injury to
podocytes occurs in many immune or non immune kidney diseases. This
results in glomerular proteinuria. Viruses like HIV, Simian SV40, Parvo
Virus B19  directly damages podocyte24.
Mutations
Mutations  in genes encoding proteins of podocyte results in
familial nephrotic syndrome. Structurally defective  podocyte and
basement membrane protein results in loss of permeability and nephrotic
range of  proteinuria. These patients are less likely responds to steroids
and progresses to end stage kidney failure25.
The most common mutation of NPHS1  gene, encoding the protein
nephrin, which is present in slit diaphragm between the podocytes.
Mutation of these genes results  in Congenital Finish NS26.
Pathophysiology
Proteinuria27,28 : Proteinuria > 150mg / 24hrs is abnormal.
Two types of proteinuria
Glomerular proteinuria due to leakage of protein through a
glomerular filteration  barrier.
21
Tubular proteinuria.Due to failure of tubular absorbtion .
Hypoalbuminimia
Massive  proteinuria results in  depletion of serum levels of
albumin beyond protein synthesis of the liver, resulting  in
hypoalbuminemia . Increased renal catabolism of filtered albumin also
leads to hypoalbuminemia.
Oedema
Due to decreased colloid oncotic pressure leads to accumulation of
fluid  in interstitial tissue.
Other factors are , sympathetic system stimulation, increased renin
secretion,  reduced natriuretic factors secretion29.
Hyperlipidemia :
Is due to increased production of lipoproteins in liver, Decreased
catabolism of lipoproteins29.
Haematuria
Due to glomerular basement membrane damage  RBCs escapes
through urine.
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Clinical features
Edema
?  In 95% of children, is the main symptom, may be
intermittent and insidious.
? First appears in the low tissue resistance areas (periorbital,
scrotal and labial areas).
? It may progress to generalized edema.
? More noticeable in the face in morning, lower extremities
later in the day typically dependent in nature30.
Gross heamaturia
? More common in MPGN, FSGS than MCD.
Respiratory distress
? Due to massive ascites , frank pulmonary edema,
effusions30 or both.
Hypertension
? More common in children with FSGS and MPGN than
MCNS31.
Others
? Fever, lethargy, abdominal pain due to peritonitis or sepsis,
anorexia, abdominal discomfort, irritability , fatigue,
diarrhorea, ascites .
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Treatment
             Oral corticosteroids plays a  major role in management of  most
children with nephrotic syndrome. The commonly used preparations are
prednisone or prednisolone . Deflacort, an oxazotic derivative of
prednisone has an anti inflammatory and immuno suppressive activity
with fewer side effects but its non availability has restricted its use.
First episode
              During 1970, ISKDC empirically recommended a protocol for
NS32,33,34. The initial episode to be treated with prednisolone of  60mg /m2
for 4weeks, daily, followed with 40mg /m2  for 3 days for another 4weeks
(intermittent therapy32,33,34).
Subsequently  a  study  conducted  by  the Arbets gemeinschaft  far
paediatrische nephrologic (APN) therapy showed that follow up was
therapy on alternate days was superior  to intermittent therapy35.
A study showed  that  prednisolone as a single morning dose was
as effective like divided doses and as well  as less side effects. Single
dose is more convenient and better drug compliance. 70% of MCD
patients achieve remission in 2 week. 75% showed relapses, or steroid
dependence. In an APN study, relapse rate will significantly lower (36
VS 62%) who received 12 week compared to 8 week steroid therapy36.
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Based on current evidence and the need to reduce steroid toxicity,
most nephrologists recommend prednisolone for 6 week daily and 6 week
alternative days (total 12 week therapy) for the initial episode13,37,38,39.
Frequent relapse steroid dependence
          Almost 50 – 60% have frequent relapses or steroid dependence
within first 6 months of initial therapy. Factors responsible are age
younger than 3 years onset, delayed time to remission after 7-9 days and
early relapse  occurrence in the first 6months after initial treatment40,41,42.
          Long term alternative day oral  prednisolone  followed with slow
tapering of prednisolone  is done to maintain dose of 0.25 – 0.5 mg/kg on
alternate days, for 9 – 12 months.
Levamisole
An antihelminthic  drug  with immune  stimulatory effects, has been
reported an effective as steroid sparing agents in number of case series
with recent review43.
        In a study with levamisole administration at a dose of 2.5mg /kg on
alternate day in 43 patient with SDNS, duration ranged 6 – 31 months, a
significant reduction in relapse rate and steroid sparing effect was
noticed44.
         The drug  is well tolerated with few side effects leucopenia ,
vasculitis rash and liver toxicity.
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Cyclophosphamide: (2-3 mg/kg)
It is an alkylating agent.Along with prednisolone(1mg/kg) on
alternate day for 8 – 12 weeks induces remission in 25 – 60%. Patients
with frequent relapses and steroid dependence needs  2 – 5 years follow
up45.
Adverse effects: bone marrow suppression, alopecia and
hemorrhagic cystitis, bacterial infections45, gonadal toxicity in pubertal
boys .
Calcineurin inhibitors (CsA)
Cyclosporine A  and  tacrolimus  act on intra cellular binding
protein  and  inhibit calcium dependent signaling  pathways  involved in
transcription of  IL2 gene.  About 80 – 85 % patients responds to CsA
dosage46  4 – 5 mg/kg daily . It requires long term therapy 1 – 3 years .
Side effects: Nephrotoxicity, which may need renal biopsy.
Mycophenolate mofetil : (MMF)
Is hydrolyzed to its  active  metabolite   Mycophenolic acid that
inhibits, inosine  monophosphate dehydrogenase, an enzyme involved in
denovo synthesis.  MMF at dose of  25  - 30 mg / kg /day, resulted in a
significant reduction in relapse  rates  and  marked  corticosteroid  sparing
effect.  Side effects were infrequent47.
26
Mendoza regimen
? Combination of  alternative  day  prednisolone  for 2 weeks oral
cyclophosphamide
? IV methyl prednisolone  30mg/kg / dose  alternate  day weekly
for 8 weeks.
? Monthly for 8 Months.
? Alternate month for 1.5 to 2  years.
? Good results have been reported using high dose IV
corticosteroid either alone or with alkylating agents.
? Complication : Hypertension, serious infections and delayed
growth.
Rituximab
? Is an anticluster of differentiation 20 monoclonal anti body ,
very effective in children with SDNS.
? Mechanism is not known. 2 to 4 doses given at an interval of 1 -
2 weeks leads to gradual remission in 50% of children.
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Table 2.Therapeutic protocols in children with steroid – resistance
nephrotic syndrome48,49,50,51,52
Type of protocol Completeresponse Side effects Comments
Methylprednisolone /
triple therapy protocol
60% Infections, cataract,
growth retardation
hypertension
82 weeks of
therapy
Cycloporine,
prednisolone
35% Nephrotoxicity 2 years of
therapy
Oral
cyclophosphamide and
alternate – day
prednisolone (ISKDC)
27% Hemorrhagic
cystitis, seizures
1 Year
 poor
response
Intravenous monthly
cyclophosphamide and
oral prednisolone
65% Nausea, vomiting,
alopecia
6 Months
Economical
Tacrolimus and
prednisolone
80% Glucose
intolerance,
hypertension,
nephrotoxicity
Less cosmetic
side effects
Rituximab 44% Infusion reaction,
anaphylaxis
Expansive
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Complications
Infections
       This is due to loss of proteins, immunoglobulin, complement and
properdin altered  T cell function, immuno suppressive therapy and
presence of edema. Peritonitis has an incidence of 2 – 6%, Cellulitis,
pneumonias, upper respiratory tract infections53.
In a study from china 54 patients with idiopathic NS were
randomized to receive standard therapy with or without IV IG (dose 100-
300  mg  /  kg/  day)  for  2  –  3days.  On  follow  up,  the  risk  of  nosocomial
infection found lower in the cases compared to controls54 (13.6% VS
46.8% P<0.05Varicella and pneumococcal (23-valent) vaccination is
recommended for all children with NS in remission or off steroid therapy.
Oral B pencillin V has been used as prophylaxis in all subjects with
persistent anasarca55.
Thromoboembolism
NS patients are at an increased risk 2–8%  for venous and arterial
thrombosis , but children are lesser risk than adults. Volume depletion,
infections, diuretic use , venepucture and immobilization aggravate the
risk of thromboembolism56.
     Evidence of thrombosis are treated with heparin followed with
warfarin for 6months or longer. Prophylactic use is not recommended.
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Hyperlipidemia
In SSNS, hyperlipidemia in transient57  but  in  SRNS,  it  persists,
contributes for cardiovascular morbidity and progression of FSGS55.
Patients are advised to reach a normal weight for height, diet restriction
in saturated fats. There is no guidelines for HMG COA reductase
inhibitors use in children58.
Osteoporosis
     The risk of steroid induced osteoporosis has long term implications
significantly. A prospective study59 from India showed 22 out of 100
patients with NS had the   features of low bone mass. Factors responsible
for osteoporosis are older age , low calcium intake and cumulative steroid
dosage59.  A recent study from USA showed, high incidence of vitamin D
deficiency in patients with NS even during remission60.
Leonard et al61 in his study concluded that intermittent use of
glucocorticoid in children does not significantly alter bone mass. From
the available evidence calcium supplementation in patients with frequent
relapses, steroid dependence or resistance, who are likely to get long term
steroid therapy is reasonable.
Outcome and prognosis
The outcome of patients with SRNS who fails to respond to high
dose steroid, cyclophosphamide  as CsA is unsatisfactory. Significant
number of patients is at risk for progression to end stage renal disease. 20
– 25 % shows recurrence with FSGS in allografts.
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ACUTE POST INFECTIVE GN (APIGN)
Other terms used are acute  nephritic  syndrome, post streptococcal
GN, Acute GN.
Etiology
Long cope et al proposed no evidence could be obtained that the
streptococcus caused by GN by actual invasion of the kidney, for blood
cultures and urine culture were negative. Dick and Dochey stated that
Beta- hemolytic  streptococci were the pathogenic species in scarlet fever
and which leads to APIGN.
Epidemiology
APIGN an important non suppurative  complication of group A
streptococcal infection 62.
? It may be sporadic or epidemic
? In world wide the incidence is  9.3 cases/ 1 lakh
? Male to female ratio in 2 - 3 :1.
? The risk of nephritis  is 25% with pyoderma and of throat
infection is 5%.
? Poor hygiene and lack of knowledge about medical care
increase the risk in developing countries.
? Group A streptococci63  are  often  typed  by  the  surface  M
protein.
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? Sero types for pyoderma – M47, M49, M55, M56, M57 and
M60.
? Sero types for pharyngitis – M1, M4, M25 and M2 strains.
? Recently epidemics of APIGN  with streptococci C, especially
streptococcus, Zoo epidimics  of unpasteurized milk of cows
with mastitis has been noted.
? The incidence has been decreased in industrialized countries
due to near eradication of  streptcoccal pyoderma due to better
hygiene and good medical care.
Table 3.Etiology of postinfectious glomerulonephritis
Bacteriae
Gram – positive bacteria
(streptococci, staphylococci,
pneumococci, listeria
monocytogenes)
Gram – negative  coccobacilli
(Haemophilus).
Gram – negative bacilli
(Salmonella, Klebsiella, Serratia,
Yersinia, Proteus, Pseudomonas).
Other infections (legionellosis,
brucellosis, bartonellosis)
Mycobacteria, Rickettsia,
Mycoplasma, Chlamydia and
spirochetes
Tuberculosis and non – tuberculous
mycobacterial infection
Syphilis (Treponema pallidum)
Leptospirosis (Leptospira
interrogans)
Rickettsial diseases (Coxiella
burnetii)
Mycoplasma pneumonia
Chlamydia pneumonia
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Fungi
Candida albicans
Histoplasma capsulatum
Coccidioides immitis
Viruses
DNA viruss
Hepatitis B, Varicella zoster and
Epstein – Barr,
Cytomegalovirus, parvovirus B19,
Adenovirus
RNA viruses
HIV
Coxsackievirus, echovirus, hepatitis
A
Dengue virus, hepatitis C virus
Mumps and measles
Parasitic infestations
Plasmodium falciparum, P.
malariae
Schistosoma haematobium, S.
mansoni
Toxoplasma gondii
Filariasis, trichinosis and hydatid
Disease
Amebiasis (Entamoeba histolytica)
Pathogenesis
In early 20th century , schick and Von pirquit64, proposed the
concepts of immune complex formation.
Theories proposed  are
1. Glomerular  trapping of circulating immune complexes.
2. Antibody mediated is situ  immune complex formation.
3. Molecular  biology.
4. Complement activation .
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Recently  two antigenic fraction have been noted as the main
factors in pathogenisis64.
Nephritis – associated plasmin receptors (NAPIr) noted as
glyceraldehyde  3 P04 dehydrogenase(GAPDH) and the streptococcal
pyogenic exotoxin B  (SPEB).
And its zymogen precursor (ZSPEB).
        NAP1r65 stimulates  the alternate complement pathway  and high
antibody titers to NAP1r  is  seen  in  95%  APIGN  patients  determined  by
western Blott.
NAP1r facilitate glomerular immune complex deposits.
SPEB 66,67is an extracelluar protein for about 90% of total protein
.High antiSPEB antibody levels and renal deposits of SPEB  are found in
APIGN.
Immune complex deposition and complement activation
Vogt et  al proposed that cationic antigen could be attracted to
penetrate the negatively charged glomerular basement membrane which
induces sub epithelial electron dense deposits and severe GN.
           Complement activation is a mainfeature in APIGN  the alternate
pathway  is  preferably  activated,  as  shown  by  low  C3  and  normal  C4
levels. Immuno flurorescence pattern shows  IgG, C3 and C5 deposition.
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Cellular immune Mechanism
Macrophages and T helper cells infiltrate the glomeruli . The
mediators IL-6, IL-8, TNF 2 plays an important role in the development
and severity of inflammation.
Auto immune reactivity
     Anti IgG antibodies are seen in severe and in glomerular deposits
frequently.     This auto immune reactivity may modulate the course of
APSGN.
Pathophysiology
  If the glomeruli gets damaged, it leads to reduction in GFR,
leading to fluid retention.  The mediators released by injured glomerlus ,
over expression of epithelial sodium channel and  interstitial
inflammatory cells also causes sodium and fluid retention by the distal
tubule which in turn cause edema and hypertension.
Clinical manifestations
Median age at presentation  at child hood  is 6 - 8 years, rare prior
to 2 years. This is attributed to the low rate  of streptococcal pharyngitis
and immature immune response . Males are more prone than females to
2:1 of unknown  cause68.
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? APIGN  characterized by gross hematuria , edema ,
hypertension,usually preceded by streptococcal pharyngitis
or pyoderma.
? Latent period in 7 – 14 days in sore throat  and while 2 – 4
weeks in pyoderma.
? Urine is classically reddish brown , smoky or cola coloured .
? Proteinuria, oliguria  may be present.
? Hypertension occurs in 80 – 90 % of cases.
? Head ache, drowsiness, seizures, mental and visual changes
occurs in 35 % of children.
? Dyspnoea, restlessness  and pulmonary edema due to extra
cellular volume expansion in over in 5% of patients.
Others: Fever ,rash, arthritis, purpura and,hepatospleenomegaly.
Investigations
?  Urine microscopic – dysmorphic RBC, RBC cast suggest
glomerular pathology low HB due to volume over load.
? Blood urea is increased 60- 65 %.
? ASO titre is higher in pharyngitis69 .
? Elevated anti DNASE in pyoderma.
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? Complement C369 in lowered but returns to normal levels with
in 6weeks onset is foremost diagnostic importance.
? 80% shows streptozyme test positive (DNAase B, streptolysin
B), hyalurinidase and streptokinase).
Renal biopsy
Indications:
? When resolution is delayed and nephritic – nephrotic
features.
? Raised BUN, severe anaemia.
? Anuria requiring dialysis.
? Systemic diseases, fever , rash, joint pain and heart diseases.
? Persistent  hypocomplementemia  to rule out MPGN or lupus
nephritis.
? Persistent Oliguria haematuria , hypertension  , gross
haematuria beyond 3 – 4weeks, azotemia beyond 2 weeks.
Light   microscopy
Diffuse hypercellullarity of endothelial and mesangial cells with
polymorpho nuclear cells. GBM is normal.
Immuno florescence
? Its show discrete granular deposits of IgG and C3 in the
capillary loop and mensangium.
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? Starry sky appearance.
? Mesangial pattern, Garland pattern.
Electron microscopy
Subepithelial humps is the hall mark finding
Management
Essentially symptomatic
? If infection is present at the time of diagnosis , Benzathine
penicillin G given as single dose 6,00000 IU for less than 27
kg.,  oral  pencillin  V 250mg 2  –  3  times  per  day  for   more
than 27 kg children for 10 days.
? Erythromycin is alternate for penicillin allergic patients .
? Restriction of fluids and sodium in take is advised  .
? Diuretics  - frusemide is needed for children with edema
hypertension and circulatory congestion.
? Antihypertensives  - Nifidipine (oral) or hydralazine
(parentral ) sodium nitroprusside is needed in hypertensive
encephalopathy.
? Hemodialysis or peritoneal dialysis may be required for
hyperkalemia , uraemia and severe circulatory congestion.
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Course and prognosis
? APIGN has excellent prognosis.
? Edema , blood pressure , starts decreasing after the 1st week
of treatment70.
? Gross haematuria clears quickly , microscopic heamaturia
may persist for many months even 6 – 12 months.
? Intermittent haematuria or proteinuria may exists which is in
significant.
? Garland pattern70 has poor out come.
? Death may occur  due to hyperkalemia  or pulmonary
edema.
? Recurrence is rare .
? APIGN patients should be followed up for proteinuria and
Blood pressure for several years.
? Renal biopsy is indicated in persistent proteinuria 70and
decline in renal function.
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ALPORT SYNDROME  (AS)
Is a heredity nephropathy71,72  under classification as collagen IV
nephropathy, initially present as haematuria.
Clinical presentation
? Micro and macroscopic haematuria,
? sensoneural hearing loss
? Ocular abnormalities.
Molecular biology
? Basement membrane of glomerulus is the effective filtration
barrier  supported by  epithelial  and  endothelial cells, made
up of type IV collagen71,72.
? Six genetically distinct type IV collagen alpha chains ?1-?6
are there, which is encoded as COL4A1  to  COL4A673.
? ?3-?6  are expressed in basement membrane of kidney,
cochlea and eyes which is responsible for clinical features of
AS.
Two  forms
?  X linked  recessive 85%  most common, involves X
chromosomes, encodes COL4A5.
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? AR or AD  - COL4A3 or COL4A4 females are affected,
responsible for thin BM nephropathy.
Clinical manifestations
? Microscopic haematuria – constant features of AS.
? Macroscopic haematuria .
? Proteinuria , hypertension.
? Bilateral progressive sensori neural hearing loss.
? Anterior lenticonus – pathognomonic of AS, Marker of
severity of AS.
Renal biopsy
Light microscopy 73: Podocytic hypertrophy and stiffness of
capillary wall followed by focal and segmental thickening of the capillary
walls.
Immunofluorescence 74: Focal deposits of IgG ,IgM or C3.
Differential Dignosis
IgA nephropathy, Membranous nephropathy, mesangio capillary
glomerular nephritis, thin BM nephritis.
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Prognosis
? Depends on mode of inheritance, gender and genetic
mutations71.
? Juvenile form progress to ESRD71 by 2-3 decades of years.
? Other form progress to CKD by 60years of age.
Treatment
? Symptomatic  treatment for auditory and ocular symptoms
and its complications.
? ACE inhibitors and ARB blockers74 as renoprotective
effects.
? Renal transplantation for ESRD.
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MEMBRANO PROLIFERATIVE GLOMERULAR NEPHRITIS :
(MPGN)
? Is an uncommon cause for chronic progressive GN in
children and young adults.
? Synonyms: Mesangio capillary GN, Lobular GN,
Hypocomplimentemia GN.
Epidemiology
? In adults it is a major cause for nephrotic syndrome.
? 0.2 – 20 % primary GN are due to MPGN in adults, 6.2% in
children.
Classification
Based on immunofluroscence .
Idiopathic or Primary – TYPE I , II & III75,76.
? Type I – Subendothelial electrondense deposits.
? Type II – Complement containing dense deposits of GM.
? Type III – Both subendothelial and subepithelial deposits.
Secondary forms
? Most common form of MPGN .
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Table 4.Etiology of MPGN
MPGN type I MPGN type II
(Dense deposit disease)
MPGN type III
Idiopathic
Familial
Secondary
Malignancy
B-Cell lymphoma
Chronic lymphoid
leukemia
Non – Hodgkin’s
lymphoma
Immunologic
SLE cryoglobuinemia
Sjogren’s syndrome
Complement deficiencies
Infections
Hepatitis B, Hepatitis C
HIV, malaria,
Shistosomiasis
Others
Heroin abuse
Partial lipodystrophy
Idiopathic
Familial
Secondary
Complement deficiencies
Partial lipodystrophy
Idiopathic
Familial
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Differential diagnosis
Lupus nephritis , hypocomplimentemia GN.
Investigations
? Complete Haemogram, ESR
? RFT,LFT, Electrolyte, Serum Cholesterol
? Complement levels C3,C4
? Antinuclear antibodies(ANA)
? Double stranded DNA(anti-ds DNA)
? Serology for HIV,HbsAg,HCV
? Renal biopsy- indicated in persistant  low complement at 8 –
12 weeks in a child with PIGN77,78
Treatment
? Angiotensin II blockers for normal kidney function.
? Long term alternate day glucocorticoid therapy.
? Eculizumab anti C3 monoclonal antibody inhibitis C5
activation.
Outcome : Irrespective of type of MPGN
? 50% progressive to ESRD 78,79by 10 years.
? 90% progressive to ESRD78,79 by 20 years.
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HENOCH SCHOLEIN PURPURA
It  is  a   disease  of  skin  ,  kidney,  joints   affecting   children
mostly.
Synonyms
Anaphylactoid Purpura ,Purpura Rheumatica, Scholein –Henoch
purpura80. Usually preceded by throat infection.Involves skin causing
palpable purpura and kidney causing hematuria,proteinuriamay
progresses to chronic kidney diseases if left untreated. It is a systemic
small vessel vasculitis80 charecterised by deposition of IgA .
Epidemiology
HSP occurs more common in children81 than adults.
Male:Female ratio is 2:1
Incidence81 :1/ 5000
Most common systemic  vasculitis in children
Etiology:   Idiopathic
Infections: Beta hemolytic streptococci,hepatitis,Herpes
simplex virus, ParvovirusB19, Coxsackievirus, Adenovirus, H.Pylori,
Measles, Mumps, Rubella, Mycoplasma.
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Drugs: NSAIDs, cefuroxime, ACEinhibitors, Vancomycin,
Ranitidine, Streptokinase.
Pathophysiology
Deposition of IgA complexes on arterioles,capillaries,and
venules81. Similar to IgA Nephropathy.
Clinical features
? Classical triad82- palpable purpura in all
cases,arthritis(80%),abdominal pain(62%)
? Purpura usually involves legs and buttocks.
? Major joints are involved,Non erosive in nature.
? Hematuria,proteinuria,Nephrotic syndrome83.1% progresses to
chronic kidney disease.
Diagnosis:
Blood tests: Elevated RFT, Raised IgA 50%, Raised CRP & ESR,
Platelets may be raised.
Biopsy of skin
? Microscopy: Hypersensitivity  vasculitis85
? Immunofluorescence:  IgA and C3 deposition85 in vessel wall.
? Renal Biopsy:  IgA deposition in mesangium85leading to
formation of crescents.
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Treatment
? Symptomatic.
? Steroids should be avoided.
? Depending upon biopsy,
? IV Methyl prednisolone,  cyclophosphamide,  dipyridamole.
? Other Regimens: Steroid/azathioprine, Steroid/
Cyclophosphamide, IVIG  is rarely used.
Prognosis:
? Good prognosis  94%  recovery84 in children.
? HSP reoccurs after 4 months of initial episode84 in children.
? In children it exhibits as nephritic /nephrotic features.
? Renal biopsy ranges from focal  mesangial  proliferative to
marked cellular proliferation with crescents85.
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IgA NEPHROPATHY
The most predominant glomerulonephritis in the world is IgA
nephropathy, also known as Berger’s disease/Berger syndrome/
synpharyngitic glomerulonephritis. 86
           The disease is characterized by the deposition of IgA antibody in
th glomerulus. While this is local, the systemic form is called the Henoch-
Schonlein Purpura(HSP), which has a more benign prognosis than IgA
which progresses to CKD in 20 yrs in about 30%of cases.
Pathogenesis
In around 50% of cases symptoms occur within two days of a non-
specific upper respiratory tract infection (the reason for it being called
synpharyngitic) not to be confused with post streptococcal
glomerulonephritis (weeks after infection).
 In a proportion, gastro intestinal or urinary tract infections can be
the trigger. These infections activate the mucosal defense mechanisms
and result in the production of IgA antibody which gets deposited in the
glomerular mesangium .
Studies show that the degalactosylation of IgA, occurring in some
in response to gut antigen exposures probably due to abnormal mucosal
antigen handling leads to the polymerization of IgA in tissues, especially
the mesangium87.  Also studies are that the IgA deposited does not appear
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to  originate  from  MALT(  which  is  the  site  of  most  URI)  but  from  the
bone marrow. This suggests an immune pathology rather than the direct
interference by outside agents.
Some studies have shown the involvement of nuclear factor-kappa
B(NF-kB) in the pathogenesis of glomerulonephritis and the increased
expression of NF-kB in the tubular area may predict poor prognosis and
decreased renal survival88.
IgA receptor abnormalities (circulating IgA –soluble CD89
complexes and over expression of the mesangial IgA1
receptor,Transferrin receptor 1) might also be responsible89.
Clinical features
? Hematuria within two days post an upper respiratory tract
infection
? Loin pain
? Persistence of microscopic hematuria even after gross hematuria
subsides.
? A proportion goes for acute renal failure.
? Some have proteinuria of <2g/day
? 5%of people present as nephrotic syndrome
? Rarely they present with chronic kidney disease.
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? Complete remission occurs only in about 5% of cases, in case of
adults. In contrast, 30-50% children show a normal urine
analysis at the end of 10yrs.
Associated diseases
? Liver failure
? Coeliac disease
? Rheumatoid arthritis
? Reiter’s disease
? Ankylosing spondylitis
? AIDS
Investigations
? History plays an important role to find out a prior URI OR UTI.
? Ultrasound of the kidney and cystoscopy are necessary to rule
out other causes of hematuria, such as malignancies or calculi.
? Finally a renal biopsy might be necessary to confirm the
disease. It shows the proliferation of the mesangium, mesangial
widening and focal and segmental inflammation. It also shows
an increase in the deposition of matrix proteins.
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? Electron microscopy confirms electron dense deposits in the
mesangium, sometimes extending to the sub endothelial regions
of adjacent capillary walls.
?  Mesangial deposition of IgA often with C3 and properdin and
smaller amounts of IgG/IgM.
? Immunofluorescence also confirms IgA deposits in the
mesangium.
? Protein electrophoresis and Ig levels assay reveals an increased
IgA in around 50% of cases.
? Urine analysis shows RBCs as casts. Proteinuria may also be
present.
? An increase in CRP, ESR, Complement levels, ANA, LDH may
also be seen.
Treatment
? Patients with isolated hematuria and proteinuria <1g/day and a
normal renal function           are just followed up annually.
?  The source of IgA (eg.tonsillitis) if identified can be treated but
this did not show better   results90.
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? To control hypertension, ACEI or ARBs can be used.Some
studies show that 6 months of steroids reduces proteinuria and
preserves renal function91.
? Cyclophosphamide, due to its side effects of malignancy and
sterility is not recommended but a combination of steroids and
cyclophosphamide initially for 3 months and then azathioprine
for the next 2 years resulted in a significant improvement in
patients with a declining GFR92.
? Some studies show that long term treatment with omega-3 fatty
acids might reduce progress but without reducing proteinuria93.
? Renal transplantations would prove beneficial but the disease
recurred in transplanted kidneys too.
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MEMBRANOUS NEPHROPATHY
It is a rare cause of asymptomatic proteinuria or NS in childhood..
Idiopathic type is more common in adults than in children.( <5%). It may
also occur secondary to SLE, Hep B infection, secondary and congenital
syphilis, malaria, EBV infection.
Incidence and prevalence in children
2/ 1lakh/ year incidence
16/ 1 lakh/ year prevalence
Gene associate with MN is HLA-DR3 in Caucasians94.
Pathogenesis
Pododcyte injury and subepitehlial immune deposits of IgG ,c395
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Table 5: Etiology of Membranous Nephropathy
Etiology Common
cause
Uncommon cause
Autoimmune
diseases
Systemic lupus
erythematosus
Rheumatoid arthritis, sjogren’s
syndrome, mixed connective –
tissue diseases, Graves’ disease,
Hashimotos thyroiditis,
dermatomyositis, myasthenia
gravis, dermatitis herpetiformis,
primary biliary cirrhosis, bullous
pemphigoid, Guillain- Barre’
syndrome
Infections Hepatitis B
Congenital
syphilis
Tuberculosis, Streptococcus,
Cytomegalovirus, hepatitis C,
Quartan malaria, schistosomiasis,
filariasis, hydatid disease, leprosy.
Drugs and toxins Non –steroidal
anti-
inflammatory
drugs
penicillamine
Captopril, gold, penicillamine,
lithium, mercury,clopidogrel,
probenecid, formaldehyde,
hydrocarbons
Miscellaneous Hematological malignancies like
lymphoma and chronic
lymphocytic leukemia, tumors,
diabetes mellitus, sarcoidosis,
sickle cell disease, hematopoietic
stem cell transplant, postrenal
transplant, C4 deficiency, selective
IgA deficiency, selective IgA
deficiency, Kimura’s disease,
sclerosing cholangitis, systemic
mastocytosis, Gardner – Diamand
syndrome
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 Pathology
Light microscopy
Histologic hallmark is diffuse glomerular capillary thickening95,96
Immunofluorescence
Uniform granular,capillary wall staining for IgG, C3
Electron microscopy
Subepithelial electron dense immune complex deposits96,97
Clinical featuresAsymptomatic proteinuria
Microscopic hematuria
Macroscopic hematuria
Table 6.Staging of membranous nephropathy based on LM and EM
Stage Light microscopy (LM) Electron microscopy (EM)
Stage I Normal GBM in thickness EDDs*-small, flat, but
discrete
Stage II Thickened GBM discernible EDDs*-bigger, flanked by
prominent
Stage III Very prominent GBM Spikes-bigger and
intramembranous, irregular
capillary wall
Stage IV GBM irregularly thickened Absent deposits, GBM
vacuolated, electroluscent BM
Stage V Return of GBM to normal Residual GBM delicate and
partially thickened
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Investigations
? Complete urinanalysis
? Spot PCR
? LFT
? Lipid profile
? Renal biopsy
? Serum electrolytes
? Complement C3
Treatment
? ACE inhibitors for HTN
? HMGCoA reductase inhibitors  for hyper cholesterolemia
? Immunosuppressants
? Ponticelli regimen96- daily i.v. methyl prednisolone  pulses for 3
days followed by alternate months of prednisolone and
chlorambucil.
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CRESCENTIC GLOMERULO NEPHRITIS (RPGN)
It is a clinical syndrome characterized by extensive crescent
formation in glomeruli resulting in rapidly progressing loss of renal
function over a short period of time.
Crescents are defined as presence of two or more layers of
epithelial cells in bowman’s space. The constituents of crescents include
coagulation proteins, macrophages, T cells, fibroblasts and parietal
epithelial cells, IL-1 and TNF98.
Classification&Etiology98
Anti-GBM GN
It is an example of cytokine- antibody mediated type 2 reaction.
Immune complex GN:
It is the most common type of crescentric GN seen in 75-80% of
patients.
Pauci- immune GN:
15-20% contribute this type.80-90% show ANCA positivity.
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Table 7.Classification and etiology of crescentic GN
Types Etiology
Anti- GBM antibody GN Anti-GBM nephritis, Goodpasture’s
syndrome
Immune complex GN Postinfectious, poststreptococcal,
infective endocarditis, visceral
abscesses, other infections like HBV,
HCV,HIV
Systemic diseases-SLE, HSP
Primary renal diseases-IgA
nephropathy, MPGN, membranous
nephritis
Pauci – immune GN Microscopic polyangiitis, Wegener’s
granulomatosis (granulomatosis with
polyangiitis),renal limited vasculitis
Clinical features
? Gross and microscopic hematuria
? Hypertension
? edema
? proteinuria
? joint pain and swelling
? seizure or altered sensorium
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Investigations
? Peripheral blood smear- normocytic normochromic anemia.
? Elevated blood urea and creatinine
? Urine shows proteinuria,  RBC or WBC casts.
? Decreased complement C3 and C4
? Raised  ASO titre.
? ANA and Anti-DNA positivity
? ANCA positivity
? Renal biopsy.
? Light  microscopy: crescents in bowman’s space.
Immunofluorescence:
? granular and sub epithelial deposits of IgG and C3 in PIGN98.
? Sub endothelial mesangial IgG and C3 deposits in MPGN
? Mesangial IgA deposits in IgA /HSP nephropathy
? A full house deposit along the capillary wall and mesangium in
lupus nephritis.
Treatment
? Supportive therapy - anti hypertensives , peritoneal dialysis for
fluid overload.
? Specific therapy.
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Treatment of crescentic GN98
Treatment Features
Supportive therapy Dialysis, control of BP with
antihypertensives, correctionof
dyselectrolytemia
Specific therapy
Induction of remission
Methylprednisolone pulses (20-30
mg/kg/day, 3-6 doses), followed by
oral prednisolone, 1.5-2mg/kg/day
for 4 week prednisolone is gradually
tapered to 0.5 mg/kg/day by
3months.
 IV pulse cyclophosphamide (500-
750mg/m²),  every  3-4  weekly  for  6
pulses
Therapeutic plasma exchange –
double volume every alternate day
for 2 week, in selected cases
Specific therapy
Maintenance
Oral prednisolone 0.5 mg/kg every
alternate day for 12-18 month
Oral azathioprine (2-3 mg/kg/day)
after pulse cyclophosphamide
therapy, for 12-18 month
Outcome
? Depends on the cause & severity98
? Post streptococcal- good outcome
? Pauci immune- one or more relapses
? Cellular and fibrocellular crescents- good outcome
61
SYSTEMIC LUPUS ERYTHEMATOSIS – LUPUS NEPHRITIS
Lupus nephritis is a serious potential feature of systemic lupus
erythematous (SLE).Systemic lupus erythematous is an autoimmune
multisystem disorder which can affect numerous organs ranging from the
kidneys, skin, pericardium, lungs, nervous system and others.
Renal involvement  might  be the first symptomatic finding  within
one year of diagnosis but sometimes within the first five years after
diagnosis.
Pathogenesis
The presence of numerous autoantibodies with the formation of
immune complexes  immune complexes.In the kidney forms the main
pathogenesis of lupus nephritis.
Classification
World Health Organization (WHO) morphologic classification of
lupus nephritis ,modified in 1982.
Class I:  Normal glomeruli
a.  Nil (by all techniques)
b.  Normal by light microscopy, but deposits by electron or
immunofluorescence microscopy
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Class II:  Pure mesangial alterations (mesangiopathy)
a. Mesangial widening and/or mild hypercellularity
b. Moderate hypercellularity
Class III: Focal segmental glomerulonephritis (associated with mild or
moderate mesangial alterations)
a. With “active” necrotizing lesions
b. With “active” and sclerosing lesions
c. With sclerosing lesions
Class IV:  Diffuse glomerulonephritis (severe mesangial, endocapillary
or mesangiocapillaryproliferation and/or extensive subendothelial
deposits)
a. Without segmental lesions
b. With “active” necrotizing lesions
c. With “active” and sclerosing lesions
Class V: Diffuse membranous glomerulonephritis
a. Pure membranous glomerulonephritis
b. Associated with lesions of class II
c. Associated with lesions of class III
d. Associated with lesions of class IV
Class VI : Advanced sclerosing glomerulonephritis
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Clinical features
Fever, hypertension or hematuria, edema of periorbital region,
anasarca, presacral edema in the morning, symptoms of renal failure..
Treatment
        The aim is to normalize renal function or to prevent further
damage. Immunosuppressive therapy forms the main line of treatment.
The American college of Rheumatolgy recommends that all lupus
nephritis patients should receive therapy with hydroxychloroquine99.
Class I requires only supportive and no specific therapy100.
Class II requires prednisolone (20-40mg/day for 1-3months if there is
proteinuria>1000mg/day.
Class III requires aggressive therapy with prednisolone 1mg/kg/day for a
month followed by tapering to a daily maintenance dose of 5-10 mg/day
for 2 yrs.methyl prednisolone in the dose of 1g/day for 3 days may be
used in acutely ill patients.
In patients in whom corticosteroids are resistant or result in toxicity
can be given immunosuppressants-cyclophosphamide ( i.v. for 6 months
and every 2-3 months thereafter ,depending on the response for 2-2.5
years.the dose is then adjusted based on hematologic response)101,
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Class IV :Mycophenolate mofetil  300-600mg/m2/dose dwice daily for
6months( to maintain control and to prevent relapses in induction
therapy-responsive patients) 100,101
Class V : patients are treated with prednisolone for 1-3 months, followed
by tapering for 1-2 years. Studies show that some patients treated with
corticosteroids and azathioprine had a complete remission, some partial
and  few resistant101
? Rituximab is being studied as a good choice for treatment.
? Other therapies under study are:
? Anti- CD20 monoclonal antibodies like ocrelizumab99,100
? Belimumab-anti-B lymphocyte stimulator.
? Atacicept- TACI-ig fusion protein
? Anticytokine therapies
Gucocorticoids should be given along with cyclophosphamide i.v.
or mycophenolate mofetil orally for induction in ISN class III/IV disease.
There is no need for immunosuppressants in class I/II patients.
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GOOD PASTURE SYNDROME
It is a rare auto immune disease in which antibodies are produced
against the basement membranes of the glomeruli and the alveoli causing
diffuse pulmonary hemorrhage and acute or  rapidly progressive
glomerulonephritis.
The disease was first described by Ernest Goodpasture, an
American  pathologist102.
Etiology
The cause is generally idiopathic but a disturbance in the alveolar
capillary permeability is necessary to allow anti GBM antibodies act on
the alveoli102. They are:
? Exposure to organic solvents like chloroform or hydrocarbons
? Exposure to tobacco smoke
? Infections such as influenza A.
? Cocaine inhalation
? Anti-lymphocytic treatment
? High content of oxygen
? Sepsis
? Metal dust inhalation
? Association with HLA-DR15 and DRB103, DRB*04103.
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Pathophysiology
The autoantibodies produced by the plasma cells bind to their
reactive epitopes in the basement membrane and activate the complement
cascade, resulting in tissue injury. This is a type II antigen antibody
reaction. The auto antibody is directed against the alpha 3 chain of type 4
collagen104. T cells might also play a role in the pathogenesis by
enhancing the B cell and antibody production.
Clinical features
? Malaise, fever, chills, arthralgia and other constituitional
symptoms
? Hemoptysis
? Massive pulmonary hemorrhage
? Dyspnoea, cough, shortness of breath
? Hematuria, edema, hypertension, uremia
? Significant anaemia.
Diagnosis
Serological assay like RIA, ELISA, anti GBM antibodies – highly
sensitive and specific.
? Western blotting on collagenase solubilised humanGBM.
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? Recombinant antigen flourescence immune assay.
? Increase in IgG1 and IgG3 subclasses.
? Anti GBM antibodies against epitopes EA  and EB and their
correlation with disease severity
? ANCA testing.
? Chest radiograph and pulmonary function testing.
? Renal biopsy- linear deposition of immunoglobins along the
GBM and crescentric glomerulonephritis.
Treatment
? Mainstay is plasmapheresis105. The plasma containing the
antibodies is filtered out and the blood cells is recycled and
given IV as a replacement fluid.
? Immunosupressants like cyclophosphamide, rituximab,
prednisolone. Cyclophospahmide 2mg/kg orally and
corticsteroids 1-1.5mg/kg.
? Renal transplantation, but post transplant anti GBM nephritis
might result.
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HEMOLYTIC UREMIC SYNDROME
HUS is a clinical syndrome characterized by progressive renal
failure associated with microangiopathic  hemolytic anaemia  and
thrombocytopenia. It is the most common cause of acute renal failure in
children106.
Most cases follow infections, sometimes bloody diarrhea. It is a
medical emergency106.
Types
? Shiga like toxin producing E.coli HUS –follows infection by
E.coli, O-157:H7
? Shiga toxin secreting strains of Shigella dysenteriae.
? Pneumococcal HUS due to infections by Streptococcus
pneumonia107.
? Atypical HUS caused by genetic defects, resulting in chronic,
uncontrolled complement activation.
Signs and symptoms
? Oliguria
? Hematuria
? Renal failure
? Thrombocytopenia
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? Microangiopathic hemolytic anaemia
? Hypertension.
? In some cases, neurologic changes.108.
Symptoms of thrombotic microangiopathy like abdominal pain,
elevated LDH, decreased  haptoglobin, anaemia, schistocytes, elevated
creatinine,  proteinuria, fatigue, confusion, nausea, diarrhea.
Pathogenesis
          The primary event is damge to endothelial cells resulting in
thrombotic micro angiopathy and RBC fragmentation. The binding of
shiga toxin to gb3 receptors of  glomerular endothelium. Signal of
cascade of events leading to apoptosis and  binding of leucocytes to
endothelial cells  which become thrombogenic   and  also cause the
release of cytokines and chemokines. Also, a metalloproteinase  called
ADAM Ts13 is inactivated causing TTP which results in reduced blood
flow to kidneys and CNS commonly.
Diagnosis
? By means of clinical symptoms
? A positive shiga toxin- EHEC test.
? Less than or equal to five percent of normal ADAMTS13 levels.
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Treatment
? Usually dialysis is required.
? Some studies say antibiotics like fluoroquinolones may be
beneficial.
? Monoclonal antibody like Eculizumab109 can  be used to treat
atypical HUS.
? Plasmapheresis
? I.V   immunoglobulins  IgG
? Fibrinolytics
? Anti platelet agents
? Corticosteroids
? Anti oxidants
? Renal transplantation
Supportive therapy:
? Fluid   and  electrolyte balance
? B.P.control
? Prophylactic phenytoin for seizure control
? Azotemia control
? Optimizing nutrition
? Splenectomy as the last resort.
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METHODS  AND  METHODOLOGY
STUDY DESIGN: Descriptive Study
STUDY PLACE: Paediatrics Department Chengalpattu Medical
College and Hospital,  Chengalpattu.
STUDY PERIOD: Sep. 2013   to  Aug. 2014
STUDY POPULATION:
INCLUSION CRITERIA:
              All children of 1-12 years with glomerular diseases admitted at
Chengalpattu medical college.
EXCLUSION CRITERIA:
                             Children <1 years
                             Children>12 years
                             Congenital heart diseases
                              Acute severe respiratory diseases
                             Acute febrile illness
                             Acute poisoning
SAMPLE SIZE: 35
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OBSERVATION
Table 8. Age  Distribution
AGE AT PRESENTATION
NO.
OF PATIENTS PERCENT
<6 yrs 28 80
>6yrs 7 20
Total 35 100
Out  of  35  patients  80%(N=28)  were  less  than  6  years  and
20%(N=7) were more than 6 years. The mean age of presentation is 4.87
Graph 1. Age  Distribution
Shows the diagrammatic representation of age distribution of study group
80%
20%
<6 yrs
>6yrs
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Table 9. Sex distribution
SEX NO.OF PATIENTS PERCENT
Male 21 60
Female 14 40
Total 35 100
        Out of 35 patients 60% (N=21) were males and 40%(N=14) were
females. Male:Female ratio is 1.5:1.
Graph 2 Sex Distribution
Shows the diagrammatic representation of sex distribution of study
group.
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Table 10. Past history-APIGN
PAST HISTORY NO.OF PATIENTS PERCENT
IMPETIGO 5 31.3
NO IMPETIGO 11 68.7
TOTAL 16 100
Out of 16 patients , 31.3% (N=5) were presented with Impetigo
history among APIGN patients prior to admission.
Graph 3.  Past history-APIGN
      Shows the diagrammatic representation of Past History with Impetigo
distribution of study   group
0 5 10 15
IMPETIGO
NO IMPETIGO
IMPETIGO
NO IMPETIGO
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Table 11.  Past history – Nephrotic syndrome
PAST HISTORY NO.OF PATIENTS PERCENT
RELAPSE 3 33.3
NO RELAPSE 6 66.7
TOTAL 9 100
Out of 9 patients , 33.3% (N=3) were presented with Relapse
history among NS patients prior to admission.
Graph 4. Nephrotic syndrome
Shows the diagrammatic representation of Relapse History
distribution of study group
0 2 4 6
RELAPSE
NO RELAPSE
RELAPSE
NO RELAPSE
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Table  12. Disease Distribution
DISEASE DISTRIBUTION
NO. OF
PATIENTS PERCENT
HAEMATURIA FOR
EVALUATION 10 28.6
POST INFECTIVE GN 16 45.7
NEPHROTIC SYNDROME 9 25.7
TOTAL 35 100
Out of 35 patients 45.7%(N=16) were Post Infective GN,
25.7%(N=9) were Nephrotic Syndrome , 28.6%(N=10) were Hematuria
for evaluation.
Graph 5. Disease Distribution
Shows the diagrammatic representation of disease distribution of
study group
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Table 13.  Symptoms  distribution
SYMPTOMS NO.OF PATIENTS
Facial puffiness 23
Cola coloured urine 3
Swelling of legs 10
Decreased urine output 11
Abdominal distension 5
Red coloured urine 14
Fever 7
Painful micturition 3
Graph 6: Symptoms  distribution
                Shows the diagrammatic representation of Symptoms
Distribution of
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Table 14. Duration of disease
DAYS NO.OF PATIENTS PERCENT
1 DAY 6 17.1
2 DAYS 13 37.1
3 DAYS 4 11.4
4 DAYS 6 17.1
5 DAYS 1 2.9
7 DAYS 5 14.3
TOTAL 35 100
Out of 35 patients , 37.1%(N=13) were presented with 2
days,17.1%(N=6) were presents with 1 day and 4 days,14.3%(N=5)
were presented with 7 days  , 11.4% (N=4) were presented with 3
days and 2.9%(N=1) were presented with 5 days.
Graph 7: Duration of disease
      Shows the diagrammatic representation of duration of disease onset of
study group
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Table 15. Urine colour at presentation
URINE COLOUR
NO.OF
PATIENTS PERCENT
NORMAL 20 57.1
COLA COLOURED 6 17.1
RED 9 25.7
TOTAL 35 100
Out of 35 patients 25.7%(N=9) were presented with Red
Coloured Urine and 17.1%(N=6) were presented with Cola Coloured
Urine.
Graph 8: Urine colour at presentation
          Shows the diagrammatic representation of Urine Colour
distribution of study group
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Table 16. Urine albumin
URINE ALBUMIN NO. OF PATIENTS PERCENT
1+ 9 25.7
3+ 5 14.3
4+ 5 14.3
Nil 11 31.4
Trace 5 14.3
Total 35 100
Out of 35 cases, around 14.3% (N=5) had Urine Albumin 3 + ,
and around 14.3% (N=5) had Urine Albumin 4 + .
Graph 9. Urine albumin
Shows the diagrammatic representation of Urine Albumin level of
distribution of study group.
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Table 17. Urine RBC/ CAST
URINE NO.OF PATIENTS PERCENT
RBC 16 45.7
CAST 8 22.8
NIL 11 31.5
Out  of  35  patients  45.7%(N=16)  were  presented  with  Urine  RBC
and 22.8%(N=8) were presented with Urine cast.
Graph 10. Urine RBC/CAST
       Shows the diagrammatic representation of Urine RBC/CAST
distribution of study group.
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Table 18. Urine culture & sensitivity
URINE CULTURE
SENSITIVITY
NO.OF
PATIENTS PERCENT
CITROTOBACTER 1 2.9
ECOLI 1 2.9
KLEBSIELLA 1 2.9
NO GROWTH 32 91.4
TOTAL 35 100
Out of 35 patients, around 91.4% (N=32) were urine culture
negative and 8.6%(N=3) were found  positive.
Graph 11: Urine culture and sensitivity
  Shows the diagrammatic representation of urine culture growth
distribution of study group.
2.9% 2.9% 2.9%
91.4%
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Table 19. Aso  titre
ASO TITRE NO. OF PATIENTS PERCENT
POSITIVE 5 14.3
NEGATIVE 30 85.7
TOTAL 35 100
Out of 35 patients, around 85.7% (N=30) were ASO titre negative
and 14.3%(N=5) were found  positive in PIGN patients.
Graph 12.Aso titre
          Shows the diagrammatic representation of ASO titre distribution of
study group
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Table 20. C-reactive protein
CRP NO. OF PATIENTS PERCENT
NEGATIVE 30 85.7
POSITIVE 5 14.3
TOTAL 35 100
  Out of 35 patients, around 85.7% (N=30) were CRP negative and
14.3%(N=5) were found  positive
Graph 13. C-reactive protein
Shows the diagrammatic representation of C-Reactive Protein
distribution of study group.
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Table 21. Complement C3
COMPLEMENT C3 NO.OF PATIENT PERCENT
NORMAL 17 77.3
LOW 5 22.7
TOTAL 22 100
Out of 35 patients 22 were done Complement C3 and  found
77.3%(N=17) were normal, 22.7%(N=5) were found low Complement
C3.
Graph 14. Complement C3
Shows the diagrammatic representation of Complement C3
distribution of study group.
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Table 22. Complement C3 - PIGN
COMPLEMENT C3 - PIGN NO.OF PATIENT PERCENT
NORMAL 6 54.5
LOW 5 45.5
TOTAL 11 100
Out of 35 patients 11 were done Complement C3-PIGN and found
54.5%(N=6) were normal, 45.5%(N=5) were found low Complement C3.
Graph 15. Complement C3 - PIGN
Shows the diagrammatic representation of Complement C3- PIGN
distribution of study group
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Table 23. Complement C3 - Haematuria
COMPLEMENT C3 -
HAEMATURIA NO.OF PATIENT PERCENT
NORMAL 3 100
LOW 0 0
TOTAL 3 100
Out of 35 patients 3 were done Complement C3-Haematuria and
found 100%(N=3) normal.
Graph 16. Complement C3 - Haematuria
Shows the diagrammatic representation of Complement  C3-
Haematuria distribution of study group .
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Table 24. Complement C3 - NS
COMPLEMENT C3 - NS NO.OF PATIENT PERCENT
NORMAL 8 100
LOW 0 0
TOTAL 8 100
Out of 35 patients 8 were done Complement C3 among NS patients
and  found 100%(N=8) were normal .
Graph 17.Complement C3-NS
       Shows the diagrammatic representation of Complement C3-NS
distribution of study group.
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Table 25. USG Abdomen
USG ABDOMEN NO. OF PATIENTS PERCENT
NORMAL 22 62.9
ABNORMAL 13 37.1
Out of 35 patients, around 62.9% (N=22) were Normal USG
Abdomen and 37.1%(N=13) were found  Abnormal.
Graph 18. USG abdomen
       Shows the diagrammatic representation of USG Abdomen
distribution of study group.
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                                         Table 26. CHEST X-RAY
CHEST X-RAY NO. OF PATIENT PERCENT
NORMAL 32 91.5
ABNORMAL 3 8.5
TOTAL 35 100
Out of 35 patients 91.5% (N=32) were Normal Chest X-ray and
8.5%(N=3) were found  Abnormal.
Figure 19. Chest X-Ray
          Shows the diagrammatic representation Chest X-ray distribution of
study group.
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Table 27. Improvement with treatment
IMPROVEMENT WITH
NUMBER OF
PATIENTS
PERCE
NT
Nil 1 2.9
Antibiotics 10 28.6
Antibiotics/antihypertensives 2 5.7
Antibiotics/antihypertensives/diuretics 8 22.9
Antibiotics/diuretics 4 11.4
Antibiotics/diuretics/steroids 7 20
Antibiotics/diuretics/steroids/mycophe
nolate mofetil 1 2.9
Antibiotics/steroids 1 2.9
Plenty of fluids 1 2.9
Total 35 100
Graph 20. Improvement with treatment
             Shows the diagrammatic representation Improvement distribution
of study group
3%
28%
6%
23%
11%
20%
3%
3%
3%
ANTIBIOTICS
ANTIBIOTICS/ANTIHYPERTEN
SIVES
ANTIBIOTICS/ANTIHYPERTEN
SIVES/DIURETICS
ANTIBIOTICS/DIURETICS
ANTIBIOTICS/DIURETICS/STE
ROIDS
ANTIBIOTICS/DIURETICS/STE
ROIDS/MYCOPHENOLATE
MOFETIL
92
Table 28.Prognosis Overall
PROGNOSIS NO.OF PATIENTS PERCENT
IMPROVED 32 91.5
REFERED 3 8.5
TOTAL 35 100
Out of 35 patients, around 91.5% (N=32) were improved Prognosis and
8.5% (N=3) were referred to higher institution.
Graph 21. Prognosis Overall
Shows the diagrammatic representation of Prognosis distribution of
study group.
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Table 29.Prognosis - PIGN
PROGNOSIS - PIGN NO.OF PATIENTS PERCENT
IMPROVED 16 100
REFERED 0 0
TOTAL 16 100
              Out of 16 patients,  100% (N=16) were found improved
Prognosis PIGN .
Graph 22. Prognosis - PIGN
Shows the diagrammatic representation of Prognosis PIGN
distribution of study group
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Table 30. Prognosis - NS
PROGNOSIS - NS NO.OF PATIENTS PERCENT
IMPROVED 7 77.7
REFERED 2 22.3
TOTAL 9 100
Out of 9 patients,  77.7% (N=7) were improved Prognosis NS and
22.3%(N=2) were referred to higher institution.
Graph 23. Prognosis - NS
Shows the diagrammatic representation of Prognosis- NS
distribution of study group.
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Table 31. Prognosis - Haematuria
PROGNOSIS - HAEMATURIA NO.OF PATIENTS PERCENT
IMPROVED 9 90
REFERED 1 10
TOTAL 10 100
Out of 10 patients, 90% (N=9) were improved Prognosis-
Haematuria and 10% (N=1) were referred to higher institution.
Graph 24. Prognosis - Haematuria
Shows the diagrammatic representation of Prognosis- Haematuria
distribution of study group  .
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Table 32. Prognosis – NS on basis of steroid response
PROGNOSIS - NS ON BASIS OF
STEROID RESPONSE
NO. OF
PATIENTS PERCENT
REMISSION 7 77.7
RELAPSE 2 22.3
TOTAL 9 100
Out of 9 patients,  77.7% (N=7) were Remitted Prognosis based on
Steroid response and 22.3%(N=2) were referred to higher institution for
Relapse.
Graph 25. Prognosis – NS on basis of steroid response
Shows the diagrammatic representation of Prognosis-NS basis on
Steroid response distribution of study group.
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DISCUSSION
1) AGE DISTRIBUTION
Out of 35 patients  80% (n=28) were less than 6 yrs and 20%(N=7)
were more than 6 yrs .the mean age of presentation is 4.87.
In copp et al study2,out of 432 children were less than or equal to
15 yrs,  the mean age of presentation 8.96.
2) Sex distribution
Out of  35 patients  60%( n=21) were males and 40% (N=14) were
females.    Male :Female ratio is 1.5 : 1,
In  fore  man   J.W  chan  JC   study  males   accounted   54%   and
females  46%., male: female  ratio is 1.2:1.
3) Past history
Out  of  35  patients  31.3%  among  PIGN  were  presented  with
impetigo and 33.3%among NS were presented with relapse history.
4) Disease distribution
In our study out of 35 patients  45.7 %(N=16) were PIGN,
28.6%(N=10)   were hematuria for evaluation,25.7(N=9)were Nephrotic
syndrome.
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5)  Symptoms distribution
In our study ,out of 35 patients, most of the patients (N=23) were
presented with peri orbital puffiness,14 were presented with red colored
urine,10 were presented with swelling of legs, 11 presented with
decreased urine output,3 were presented with  cola colored  urine ,7 were
preseted with fever, 5 were presented with abdominal distension, 3 were
presented with painful micturition.
6)  Duration of disease
Out of 35 patients  37.1% were presented on day 2 of
symptoms,14.3% were presented on 7th day. Urine color at presentation
out of 35 patients ,25.7% presented with red color urine,17.1% were
presented with cola colored urine.
7) Urine  Albumin
Out of 35 patients in our study 14.3 % (N=5) presented  4+ urine
albumin , 14.3%(N=5) with 3+ urine albumin.
In Yong –hoog Park et al study, total 1044 school children were
screened for proteinuria ,reported as 26.4% were found having isolated
protenuria ,13.5 % were found having  both protenuria and  hematuria.
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8) Urine culture and sensitivity:
out  of   35  patient  s   8.6%  (N=3)  were   presented  with   positive
urine culture  found positive with Klebsiella,Ecoli,Citrotobacter. 91.4%
were presented with no growth.
9) ASO titre
Out of 35 patients, 14.3% were presented with positive titre among
PIGN,85.7% were presented withnegative titre,no positive titre was found
among  NS/Haematuria for evaluation.
In  Schoff  et  al  study  ,  150  cases  were  studied  for  a  period  of  3
years elevation of ASO titre  was significantly higher to 96% in  PIGN .
10)  C reactive protein
Out of 35 patients 85.7% (N=30) were found CRP  negative and
14.3% were found positive CRP among PIGN.
11) USG  abdomen and chest xay
Out  of  35   patients   62.9%  (N=22)   were  found  normal   USG
abdomen  and 31.7%(N=13) were found  abnormal with pleural effusion,
hepatospleenomegaly among NS  patients, bladder wall thickening  for
hematuria evaluation .
Chest xray showed  8.5%(N=3) were found abnormal and  91.5
%(N=32) were found normal with  pleural effusion among NS  patients.
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12) Complement C3
Out  of  35 patients, 22 were done serum complement,among this
77.3%(N=17) were found normal in both NS and PIGN patients.
22.7%(N=5) were found low complement values among PIGN pteints.
After 6 weeks,repeat complement C3 test was done,Low complement
patients were found normal C3 values in 100% patients. In Schoff et al
study , 150 cases were studied for a period of 3 years c3 values are lower
in 88% of children of PIGN  and returned to normal in 95%.
13) Improvement with treatment
Out of 35 patients,28.6% were improved with antibiotics,5.7%
were improved with only antihypertensive alone,11.4% were improved
with diuretics alone,22.9% were improved with antihypertensives and
diuretics, 2.9% steroids alone, 20% were improved with diuretics and
steroids,  2.9% were improved with diuretics, steroid and mycophenolate
mofetil,2.9% were improved only with fluids.
14) Prognosis
Out of 35 pateints,91.5% were improved with proper management,
8.5% were referred to  higher institution for follow up care. Among PIGN
patients, (N=16) patients were improved with antibiotics, antihyper
tensives and diuretics. None were referred.
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Among NS,77.7% were improved with diuretics and steroids and
found remitted. 22.3% were found steroid dependent. Among haematuria
for evaluation,90%were improved with proper management.10% were
referred to higher institution as that child had recurrent haematuria and he
was evaluated for ? IgAnephropathy for whom renal biopsy  is advised.
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SUMMARY
In our study, 35 patients who admitted or complaints of glomerular
symptoms were taken. Out of this, 16 patients were diagnosed as PIGN,9
were NS and 10 were found haematuria for evaluation.
Among  16  PIGN  patients,  all  patients  were  improved.7  out  of  9
patients were found remitted among NS patients, 2 were referred to
higher institution, they were found to be steroid dependent NS.
Among 10 haematuria for evaluation cases 9 were improved, only
one was referred to higher institution for recurrent haematuria for whom
renal biopsy was advised. On following up that child they have not done
renal biopsy till now.
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CONCLUSION
Based on the results of our study  we conclude that,
? Our clinical profile is concordant with glomerular diseases in
children.
? Both PIGN &Minimal change NS in children can be properly
evaluated and treated promptly  which shows better outcome in our
study.
? Early diagnosis, proper treatment, and regular follow up care
prevents end stage kidney disease among children.
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CASE PROFORMA
I.PNO:
NAME :
AGE :
SEX :
ADDRESS :
PH   No. :
DATE OF ADMISSION :
DATE OF DISCHARGE/REFERRAL :
INFORMANT :
REFERRED FROM :
PRE HOSPITAL TREATMENT :
NATIVE TREATMENT :
IN PATIENT :
OUTPATIENT :
REFERRAL DIAGNOSIS :
PROVISIONAL DIAGNOSIS :
FINAL DIAGNOSIS :
CHIEF COMPLAINTS :
121
HISTORY	OF	PRESENTING	ILLNESS	
GASTRO INTESTINAL YES NO DURATION
VOMITING
JAUNDICE
ABDOMINAL PAIN
SWELLING IN ILIAC
LOOSE STOOLS
ABDOMINAL
BLOOD IN STOOLS
BLOOD IN VOMIT
CONSTIPATION
RENAL SYSTEM YES NO DURATION
FACIAL PUFFIN ESS
NOT PASSED URINE
RED COLOURED URINE
WHITE COLOURED
PAINFUL MICTURITION
POLYURIA/POLYDIPSIA
NOCTURNAL
FOULSMELLING URINE
122
RESPIRATORY SYSTEM YES NO DURATION
FEVER
COUGH/COLD
DIFFICULTY IN
BREATHING
CHEST PAIN
CARDIOVASCULAR SYSTEM YES NO DURATION
CHEST PAIN
DYSPNOEA
ORTHOPNOEA
PND
PALPITATION
CENTRAL NERVOUS SYSTEM YES NO DURATION
HEADACHE
FACIAL WEAKNESS/ HEMIPLEGIA
LOSS OF CONSCIOUSNESS
CONVULSIONS
ALTERED SENSORIUM
BLINDNESS
VOMITING
123
OTHERS: YES NO DURATION
IRRITABILITY
FAILURE TO THRIVE
BONY DEFORMITIES
PAST HISTORY: YES NO DURATION
SIMILAR ILLNESS
SORE THROAT
SKIN INFECTION
JAUNDICE
FEVER WITH RASH
UTI
H/O S/O INFECTIVE ENDOCARDITIS
GUM BLEEDING/BONE PAIN
FEVER WITH ARTHRALGIA
FAMILY HISTORY: YES NO DURATION
SIMILAR ILLNESS
TB CONTACT
BIRTH HISTORY : LN/LSCS :
ADMISSION IN NICU :
DEVELOPEMENTAL HISTORY     :
IMMUNISATION HISTORY :
124
CLINICAL EXAMINATION: YES NO
CONSCIOUS
ALERT/LETHARGIC
FEBRILE
WELL/MALNOURISHED
FACIAL PUFFINESS
ANAEMIA
CLUBBING/CYANOSIS
JAUNDICE
IMPETIGO/RASH .<,
LYMPHADENOPATHY
PEDAL EDEMA
TONSILLITIS
PETECHIAE/PURPURA
VITALS ANTHROPOMETRY:
HR: HEIGHT: MAC:
RR: WEIGHT: HC:
JVP: AT ADMISSION: AC
TEMP: AT DISCHARGE: CC
BP:
125
SYSTEMIC EXAMINATION: YES NO
CVS: SI S2
MURMUR
OTHERS/GALLOP
RS:   BAE
ADDED SOUNDS
P/A: SOFT
DISTENSION
HEPATOMEGALY
SPENOMEGALY
FLUID THRILL
SHIFTING DULLNESS
CNS:TONE
PERL
NEUROLOGICAL DEFICIT
GENITOURINARY:  ULCERS
PHIMOSIS/PARA PHIMOSIS
SWELLING
SCROTAL/VULVAL EDEMA
INGUINAL NODES
B/LCRYPTORCHIDISM
126
INVESTIGATIONS:
DATE:
CBC:TC
DC
ESR
HB
PCV
PLATELET
PERIPHERAL SMEAR
URINE: SUGAR
ALBUMIN
DEPOSITS
MACROSCOPIC EX:
COLOUR
MICROSCOPIC EX:
RBC
WBC
CASTS
URINE PROTEIN   :
SPOT PCR
24 HR URINE
PROTEIN
URINE C/S
BLOOD UREA
SERUM CREATININE
SERUM
ELECTROLYTES
SERUM
CHOLESTEROL
TOTAL PROTEIN
ALBUMIN
GLOBULIN
ASO TITRE
ANTI DNASETEST
MANTOUXTEST
CRP
C3 LEVEL
C4 LEVEL
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IMAGING STUDIES:
DATE:
PLAIN XRAY CHEST
USG ABDOMEN
IV PYELOGRAM
MCU
RADIONUCLEOTIDE
IMAGING
RENAL BIOPSY
ECG
ECHO
CT SCAN
OTHERS
MANAGEMENT : DURATION
BED REST :
SALT RESTRICTION :
FLUID RESTRICTION :
T.FUROSEMIDE :
T.NIFEDIPINE :
ANTIBIOTICS-PENICILLIN :
ERYTHROMYCIN :
STEROIDS-PREDNISOLONE :
CONDITION AT DISCHARGE :
CLINICAL PROFILE AND OUTCOME OF GLOMERULAR DISEASES IN CHILDREN ADMITTED--SEP2013-AUG2014----MASTER CHART
S. No Name Age Sex Diagnosis Symptoms Duration Past/Family History Signs AD DIS
1 Praveen Kumar 3 1/2 M H.E Red coloured urine 1 Day Peri orbital puffiness 90/70 90/70
2 Naresh 4 M PIGN
Red coloured urine , facial
puffiness ,abdominal distention 1 Day Impetigo 10 days back
Peri orbital
puffiness/healed
impetigo scars legs 130/100 100/70
3 Deepika 4   1/2 F NS Facial puffiness/ swelling of legs 2 Days Similar history 6 months back
Peri orbital puffiness/
B/L pedal edema 90/70 90/70
4 Krishka 1   1/2 F NS Facial puffiness/ swelling of legs 2 Days
Periorbital
puffiness/b/l pedal
edema 90/70 90/70
5 Vignesh 9 M HE Cola coloured urine/fever 1 Day
Similar history 18  months
back/treated for PIGN
Peri orbital
puffiness/swelling of
legs 90/70 90/70
6 Varadharaj 4 M PIGN
Facial puffiness/ swelling of
legs/decreased urine o/p 3 Days
Peri orbital
puffiness/lt
submandibular node 100/90 90/70
7 Thavasree 3 F HE Red coloured urine 3 Days 90/60 80/60
8 Deepak 6 M PIGN
Facial puffiness/swelling of
scrotum 3 Days
Peri orbital
puffiness/impetigo
legs 130/90 100/60
9 Ramachandran 11 M PIGN
Facial puffiness/swelling of
legs/decreased urine o/p 2 Days
Peri orbital
puffiness/impetigo
legs 128/90 90/60
10 Elangovan 6 M HE
Red coloured urine/pain during
micturition 7 Days Peri orbital puffiness 94/70 90/60
11 Kavisree 6 F PS
Facial puffiness/red coloured
urine 7 Days Peri orbital puffiness 94/70 90/60
BP
12 Malini 5 F SDNS
Facial puffiness/decreased
urine o/p/swelling of
legs/abdominal distension 1 Day Similar history 6 months back
Peri orbital
pufiness/B/L pedal
edema 90/60 80/60
13 Kamelesh 3 M PIGN
Red coloured urine/facial
puffiness/decreased urine o/p 2 Days Peri orbital puffiness 120/70 90/60
14 Ajay 10 M PIGN Facial puffiness 7 Days peri orbital puffiness 120/80 100/70
15 Rithika 5 F PIGN
Facial puffiness/red coloured
urine 4 Days  Peri orbital puffiness 140/100 90/70
16 Likesh 2 M PIGN Facial puffiness/swelling of legs 4 Days
Peri orbital
puffiness/B/L pedal
edema 120/80 90/70
17 Jothipriya 6 F PIGN
Facial puffiness/decreased
urine o/p 4 Days
Peri orbital
puffiness/B/L pedal
edema 140/90 100/70
18 Kishore 4 M PIGN Facial puffiness 4 Days
Peri orbital
puffiness/B/L pedal
edema 100/70 90/60
19 Vijay 8 M NS
Facial puffiness/decreased
urine/abdominal distension 4 Days Fever with rash 2 weeks back
Peri orbital
puffiness/healed
impetigo scars legs 110/70 100/70
20 Dharshan 3   1/2 M HE
Red coloured urine/painful
micturition 2 Days 90/60
21 Dilipan M HE Red coloured urine 1 Day 90/50
22 Stalin 9 M NS
Facial puffiness/decreased
urine o/p/swelling of legs/fever 4 Days
Peri orbital
puffiness/b/l pedal
edema/b/l scrotal
swelling 120/80 100/60
23 Raja 2 M NS
Facial puffiness/decreased
urine o/p/swelling of legs/fever 5 Days H/o dog bite 1week back
Peri orbital
puffiness/b/l pedal
edema 120/80 90/70
24 Suriya 7 M PIGN Cola coloured urine/fever 3 Days Healed impetigo legs 100/70 90/70
25 Prathesh 6 M PIGN
Facial puffiness/decreased
urine o/p/swelling of legs/fever 2 Days Impetigo 1 week back
Peri orbital
puffiness/healed
impetigo scars legs 90/70 80/70
26 Vigneshwaran 3   1/2 M NS
Red Coloured urine/facial
puffiness 2 Days Peri orbital pufiness 100/70 90/80
27 Deepika 6 F PIGN Cola coloured urine/fever 2 Days Healed impetigo legs 130/50 90/70
28 Jeevan 2   1/2 M HE Red coloured urine 2 Days 90/60 90/70
29 Gopika 6 F HE Red coloured urine 2 Days 90/70 90/70
30 Setharaman 7 M PIGN
Facial pufiness/fever/painful
micturition 7 Days Periorbital puffiness 100/70 90/70
31 Jesintha 3 F NS
Facial puffiness/abdominal
distension 1 Day Periorbital puffiness 90/70 90/70
32 Hemavathy 3 F SDNS
Facial puffiness/abdominal
distension/swelling of
legs/decreased urine output 7 days Similar illness 1 yr back
Periorbital
puffiness,abd.distensi
on,b/l pedal edema 90/70 90/60
33 Manisha 1.6 F HE Red coloured urine 2 days 90/70 90/60
34 Abinaya 2 F HE Red coloured urine 2 days 90/60 90/70
35 Padmapriya 4 F PIGN
Red coloured urine/facial
puffiness/decreased urine o/p 2 days Impetigo legs 10 days back
Periorbital puffiness,
healed impetigious
lesions 130/80 100/80
CLINICAL PROFILE AND OUTCOME OF GLOMERULAR DISEASES IN CHILDREN ADMITTED--SEP2013-AUG2014----MASTER CHART
AD Dis Hb % Macro Albumin Deposits Spot PCR
24
Hours
Culture
Sensitivity
 Urea Creatinine
Serum
Electolytes
Serum
Cholestrol
NEC
12 12 12.1 Red 1+ 4-6 EPI/5-6RBC s 0.3 370 Klebsiella 18 1.1 N 161 No Growth
14 12.5 9.9 Cola coloured Nil
1-2
Puscells/Cast/6-8
RBC s 2.6 280 No Growth 46 1.1 N 139 No Growth
15 13 12.3 4+ 1-2 Puscells 8.5 870 No Growth 19 0.8 N 207 No Growth
9 7.5 10.0 4+ 2-3 Puscells 27.5 920 No Growth 22 0.8 N 326 No Growth
24 24 10.4 Red Nil
2-3
Puscells/Cast+/ 4-
5 RBCs 2.5 250 No Growth 29 1.0 N 120 No Growth
14 13.5 8.0 Trace
2-3 Puscells/2-4
RBC s 0.2 180 No Growth 19 0.7 N 160 No Growth
12 11.5 9.9 Red Trace
4-8 Puscells/5-10
RBC 0.3 90 No Growth 21 0.8 N 168 No Growth
18 17 8.8 1+
4-5 Puscells/4-5
RBCs 1.8 120 Citrotobacter 55 1.1 N 128 No Growth
24 24 11.0 1+ 1-2 EPI 0.4 64 No Growth 24 0.7 N 100 No Growth
18 18 11.5 Trace
2-3 Puscells/5-6
RBCs 0.5 320 No Growth 22 1.0 N 132 No Growth
17 16 11.2 1+
2-3 Puscells/2-3
RBC 1.3 168 No Growth 54 1.5 N 148 No Growth
Urine BloodWeight
20 17 12.6 3+ 6-8 Puscells 3.7 1290 No Growth 24 0.8 6.5/5.1 341 No Growth
12 12 9.9 Cola coloured 1+ RBC Cast 1.4 300 No Growth 55 0.9 N 128 No Growth
25 25 10.0 Nil 1-2 Puscells 0.5 190 No Growth 20 0.8 N 100 No Growth
16 15 10.4 Cola coloured Trace
2-3 Puscells/4-
5RBCs 0.1 200 No Growth 28 0.8 N 174 No Growth
10 9 9.4 Nil
1-2
Puscells/Cast/6-8
RBC s 0.2 128 No Growth 27 0.5 N 166 No Growth
18 17 11.2 1+
1-2
Puscells/Cast/4-6
RBC s 0.4 350 No Growth 37 0.6 N 126 No Growth
14 13 10.9 1+
2-4 Puscells/cast/5-
6 RBCs 0.6 98 No Growth 20 0.8 N 132 No Growth
24 23 14.1 3+ 1-2 Puscells 3.6 1528 No Growth 17 0.7 N 320 No Growth
13 13 11.0 Red Nil
1-2 Puscells/4-5
RBCs 0.4 90 No Growth 33 0.8 N 120 No Growth
8 8 10.8 Red Nil
1-2 Puscells?3-5
RBCs 0.2 100 Ecoli 27 0.7 N 100 No Growth
26 23 14.8 4+ 2-3 puscells 4.8 1640 No Growth 21 0.8 N 478 No Growth
10 9 11.0 4+ 1-2 Puscells 3.0 670 No Growth 49 0.6 N 387 No Growth
20 20 9.6 1+
2-3 Puscells/8-10
RBC 1.8 108 No Growth 23 1.1 N 128 No Growth
18 17 11.4 Cola coloured Nil 2-3 Puscells/ cast 0.4 128 No Growth 40 0.9 N 140 No Growth
13 12 13.0 3+ 4-5 Puscells 7.1 920 No Growth 23 0.6 N 398 No Growth
17 15 11.2 Cola coloured 3+ 2-3 Puscells/ cast 2.1 312 No Growth 28 0.8 N 154 No Growth
13 13 10.0 Red 1+ 4-5 Puscells 2 No Growth 19 0.6 N No Growth
20 20 13.8 Red Trace 4-5 RBC 0.4 No Growth 19 0.5 N No Growth
20 20 9.8 Nil 1-2 Puscells 0.5 120 No Growth 59 1.0 N No Growth
13 10 10.6 3+ 1-2 Puscells 8.3 1220 No Growth 15 0.6 N 315 No Growth
16 13 8.2 4+ 6-8 pus cells 3.8 1430 no growth 29 0.9 N 320 No Growth
10 10 12.0 Red Nil 2-5 pus cells No Growth 30 0.9 N
11 11 10.8 Red Nil 4-8 pus cells 0.8 168 No Growth 26 0.8 N 132 No Growth
15 14 12.0 Cola coloured Nil 2-3 pus cells 2 198 No Growth 52 1.4 N 148 No Growth
LFT ASO CRP USG Abdomen Chest X-ray PROGNOSIS improve ment with duration
7/3.6/3.4 N N Bladderwall thikening NAD Improved Antibiotics D5-D12
6/3.2/2.8 400 IU N
Rt  Pleural
effusion/spleenomegaly NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D14
6.6/3.6/3.0 N N 114 ( N ) Rt pleural effusion/ascites NAD Improved Antibiotics/Diuretics/Steroids REMITTED
7/4.8/2.2 N N 132 ( N ) NAD NAD Improved Antibiotics/Steroids REMITTED
N N NAD NAD referred Antibiotics D1-D10
6.8/3.5/3.3 N N NAD NAD Improved Antibiotics D1-D7
5.6/3.0/2.6 N N NAD NAD Improved Antibiotics D1-D5
6.4/3.9/3.5 N N b/l pleral effusion/ascites RT Pleural Effusion Improved
Antibiotics/Antihypertensives/Di
uretics D1-D10
N N 122 ( N ) NAD NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D7
6.2/3.2/3.0 N N NAD NAD Improved Antibiotics D2-D6
6.4/3.9/2.5 400 IU N 154 ( N ) NAD NAD Improved Antibiotics/Antihypertensives D2-D7
Compliment C3
Imaging Studies
6.8/2.4/4.4 N N 142 ( N ) NAD NAD Refered
Antibiotics/diuretics/Steroids/M
ycophenolate mofetil SEROID DEPENDENCE
7/3.8/3.2 N N 106 ( N ) NAD NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D14
6.4/3.2/3.2 N N Rt pleural effusion NAD Improved Antibiotics/Diuretics D1-D7
5.3/3.8/1.5 N N 85 130 B/L pleural effusion/ascites NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D7
6.5/3.9/2.6 N Positive 102.3 ( N )
b/l pleral
effusion/hepatospleenomegal
y NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D10
6.3/4.3/2 N N 91.4 ( N ) NAD NAD Improved
Antibiotics/Antihypertensives/Di
uretics D1-D8
5.6/3.2/2.4 N N 19.8 121.4 NAD NAD Improved Antibiotics/Diuretics D1-D8
6.5/3.2/2.4 N N 102 ( N ) Rt pleural effusion/ascites LT Pleural Effusion Improved Antibiotics/Diuretics/Steroids REMITTED
6.5/3.8/2.7 N N NAD NAD Improved plenty of fluids
N N NAD NAD Improved Antibiotics D1-D7
6.8/2.1/4.7 N N 123 ( N ) Ascites/HSM NAD Improved Antibiotics/Diuretics/Steroids REMITTED
6.6/2.8/3.8 N N 98.7 ( N ) NAD NAD Improved Antibiotics/Diuretics/Steroids REMITTED
6.5/3.6/2.7 400 IU N 71.1 93.7 NAD NAD Improved Antibiotics/Diuretics D1-D12
6.1/4.0/2.1 N Positive Spleenomegaly NAD Improved Antibiotics/Diuretics D1-D7
6.6/2.2/4.4 N N NAD NAD Improved Antibiotics/Diuretics/Steroids REMITTED
6.5/4.4/2.1 400 IU N 81.4 180.1 NAD NAD Improved Antibiotics/Antihypertensives D1-D7
Bladderwall thikening NAD Improved Antibiotics D1-D5
6.8/4.0/2.8 103.5  ( N ) Bladderwall thikening NAD Improved
6./3.0/3.7 N N 89.7  ( N ) NAD NAD Improved Antibiotics D1-D7
6.9/2.8/4.1 N N 169.5  ( N ) NAD NAD Improved Antibiotics/Diuretics/Steroids REMITTED
6.6/2.0/4.6 N N 108(N) Rt side pleuraleffusion ASCITES/HEPATOMEGALY Refered Antibiotics/Diuretics/Steroids SEROID DEPENDENCE
N 99.3 NAD NAD Improved Antibiotics D1-D7
6.0/3.2/2.8 N 125(N) NAD NAD Improved Antibiotics D1-D7
6.8/3.5/3.3 400IU positive 64.7 120 NAD NAD Improved
Antibiotics/Antihypertensives/Di
uretics D2-D8
